All In MedTech

Device Trial Radar · NCT07354178

Study of Collagen-Based Thrombin Hemostat for the Control of Bleeding in Spinal Surgery

Randomized Clinical Trial to Assess Hemostasis by Applying Collagen-based Thrombin-containing Hemostat in Spinal Surgery

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

130

Actual

Start

Oct 22, 2024

Primary completion

Jun 19, 2025

Study completion Aug 18, 2025

Sponsor

Lead sponsor
DALIM TISSEN Co., Ltd.Not on our public-company list
Sponsor type
Industry
First posted
Jan 21, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial evaluated the effectiveness and safety of a collagen-based hemostatic agent containing thrombin in patients undergoing spinal surgery. The study compared this investigational product with an existing hemostatic agent to assess whether it performed equally well in controlling surgical bleeding. Patients with spinal stenosis, tumors, or trauma who required spinal surgery were enrolled. The hemostat was applied intraoperatively when grade 3 bleeding was observed. The study assessed hemostatic performance and safety of the product when used during surgery.

Conditions

  • Spinal Tumor
  • Spinal Injury
  • Hemostasis
  • Spinal Stenosis
  • Spinal Surgery
  • Intraoperative Bleeding

Interventions

  • CollaStat®Device

    Clinical subjects are enrolled after the clinical investigator confirms that there are bleeding sites where hemostasis by normal procedures (compression, suturing, electrosurgical scalpel, etc.) is ineffective or difficult to perform. To arrest intraoperative bleeding, the study group is treated with Dalim Tissen's CollaStat® and compressed with general gauze.

  • Floseal®Device

    Clinical subjects are enrolled after the clinical investigator confirms that there are bleeding sites where hemostasis by normal procedures (compression, suturing, electrosurgical scalpel, etc.) is ineffective or difficult to perform. To arrest intraoperative bleeding, the control group is treated with Baxter's Floseal® and compressed with general gauze

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hemostasis success rateTime frame: Hemostasis at the first bleeding site is confirmed at 1 minute, 2 minutes, 3 minutes, 6 minutes, and 10 minutes

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Gangnam Severance Hospital

    Seoul, Gangnam-gu, South Korea

  • Yongin Severance Hospital

    Yongin-si, Giheung-gu, South Korea

  • Severance Hospital, Yonsei University Health Syetem

    Seoul, Seodaemun-gu, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.